Department of Laboratory Medicine, Department of Tissue Bank, Affiliated Hospital of Nantong University, School of Public Health, Nantong University, Nantong, Jiangsu, PR China, 226001.
Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, PR China, 226001.
Hum Pathol. 2018 Jan;71:135-144. doi: 10.1016/j.humpath.2017.10.032. Epub 2017 Nov 8.
The role of BRCA1 and BRCA2 genes is mainly to maintain genome integrity in response to DNA damage through different mechanisms. Deregulation of BRCA1 and BRCA2 is associated with the development of tumor and altered sensitivity to chemotherapeutic agents. In this study, we determined protein expression of BRCA1 and BRCA2 in 4 digestive system cancers (gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic cancer) by immunohistochemistry on tissue microarrays. A total of 1546 samples of 4 types of cancer tissues, their matched adjacent nontumor tissues, and corresponding benign tissues were studied, respectively. Immunohistochemistry expression patterns of the 2 proteins and their correlation with patients' clinical parameters and overall survival were analyzed. The results showed that low expression of cytoplasmic BRCA1 and BRCA2 was commonly associated with advanced tumor-lymph node-metastasis stage, whereas high expression of nuclear BRCA1 was generally correlated with advanced tumor stages in these cancers. High expression of cytoplasmic BRCA1 and BRCA2 had significantly favorable overall survival in digestive system cancers; in contrast, BRCA1 nuclear expression usually predicted poor outcomes. We conclude that BRCA1 and BRCA2 could be used as clinicopathological biomarkers to evaluate the prognosis of digestive system cancers.
BRCA1 和 BRCA2 基因的作用主要是通过不同的机制来维持基因组的完整性,以应对 DNA 损伤。BRCA1 和 BRCA2 的失调与肿瘤的发生发展以及对化疗药物敏感性的改变有关。在这项研究中,我们通过组织微阵列免疫组织化学方法检测了 4 种消化系统癌症(胃癌、结直肠癌、肝细胞癌和胰腺癌)中 BRCA1 和 BRCA2 的蛋白表达。共研究了 4 种癌症组织、其配对的非肿瘤组织和相应的良性组织的 1546 个样本。分析了这两种蛋白的免疫组织化学表达模式及其与患者临床参数和总生存期的相关性。结果表明,细胞质 BRCA1 和 BRCA2 的低表达通常与肿瘤-淋巴结-转移分期较晚有关,而核 BRCA1 的高表达通常与这些癌症的较晚肿瘤分期有关。细胞质 BRCA1 和 BRCA2 的高表达与消化系统癌症的总生存期显著相关良好;相反,BRCA1 核表达通常预示着不良预后。我们得出结论,BRCA1 和 BRCA2 可作为临床病理生物标志物,用于评估消化系统癌症的预后。